Summary
ABCL Chart
AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript
AbCellera Biologics Inc. ( ABCL ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Tryn Stimart - Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Carl L. Hansen - CEO, President & Chairperson Andrew Booth - Chief Financial Officer Conference Call Participants Malcolm Hoffman - BMO Capital Markets Equity Research Andrea Tan - Goldman Sachs Group, Inc., Research Division Joshua Nickerson - Stifel, Nicolaus & Company, Incorporated, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Jacqueline Kisa - TD Cowen, Research Division Presentation Operator Good afternoon, and welcome to AbCellera's Third Quarter 2025 Business Update Conference Call.
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.17 per share a year ago.
AbCellera Biologics: Entering Growth Phase After A Pause
AbCellera Biologics is poised for long-term growth as its clinical manufacturing facility nears completion, enabling in-house drug development and contract manufacturing revenue. ABCL's strategic pivot from a service provider to a proprietary drug developer targets high-growth monoclonal antibody markets, with promising candidates ABCL635 and ABCL575 entering clinical trials. Despite recent revenue and net income declines due to the business model shift, ABCL is well-funded and expects revenue to double in 2026 as clinical batches commence.
AbCellera Biologics Inc. (ABCL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AbCellera Biologics Inc. ever had a stock split?
AbCellera Biologics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Carl L.G. Hansen CEO | NASDAQ (NGS) Exchange | 00288U106 CUSIP |
| CA Country | 596 Employees | - Last Dividend | - Last Split | 11 Dec 2020 IPO Date |
Overview
AbCellera Biologics Inc. is a pioneering entity in the biotechnology sector, focusing on revolutionizing the approach towards antibody drug discovery and development. The company leverages a unique engine that harnesses the power of natural immune responses to discover antibodies. This innovative platform is not only capable of identifying these vital antibodies but also pre-enriches them, streamlining the path from discovery to development. Since its inception in 2012, AbCellera has established itself as a key player in the biotech industry, forming strategic alliances with prominent companies like Eli Lilly, Confo Therapeutics, and Biogen Inc. These collaborations aim to accelerate the discovery of therapeutic antibody candidates across various medical conditions, including metabolic and endocrine disorders, atopic dermatitis, and neurological conditions. Headquartered in Vancouver, Canada, AbCellera continues to push the boundaries of medical science, charting new territories in antibody discovery and drug development.
Products and Services
AbCellera Biologics Inc. offers a range of preclinical products and services aimed at tackling some of the most challenging conditions in the medical field today. The company's expertise in antibody discovery and development has enabled the inception of several promising preclinical candidates, along with strategic partnerships focused on advancing therapeutic solutions.
- ABCL635 - This preclinical product is designed to address metabolic and endocrine conditions. Leveraging AbCellera's antibody discovery engine, ABCL635 represents a significant step forward in the treatment of diseases that affect millions of people worldwide.
- ABCL575 - Focused on atopic dermatitis, ABCL575 emerges from the company's platform as another testament to its innovative approach towards treating complex skin conditions. This product embodies AbCellera's commitment to providing relief to those afflicted by atopic dermatitis.
In addition to these preclinical products, AbCellera's strategic collaborations underline its role as a versatile partner in the drug discovery process:
- Eli Lilly and Company: A research collaboration and license agreement focused on the development of antibody-based therapies. This partnership highlights AbCellera's capability in bringing its discovery engine to bear on large-scale pharmaceutical development projects.
- Confo Therapeutics: This research collaboration is aimed at discovering therapeutic antibody candidates targeting two undisclosed GPCR targets. It showcases AbCellera's adaptability in exploring new therapeutic areas and potential targets.
- Biogen Inc.: A strategic collaboration with Biogen underscores AbCellera's expansion into neurological conditions, leveraging its antibody discovery and development expertise to tackle some of the most pressing challenges in neurology.
Contact Information
